CASI Pharmaceuticals Has Entered Into An Exclusive Distribution Agreement With China National Medicines Corporation Ltd. For The Distribution Of Pralatrexate For Injection In China, Excluding Hong Kong SAR, Taiwan, And Macau, For A Period Of One Year
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals has signed an exclusive one-year distribution agreement with China National Medicines Corporation Ltd. for Pralatrexate for Injection in mainland China, excluding Hong Kong SAR, Taiwan, and Macau, as per an SEC filing.
December 08, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CASI Pharmaceuticals' exclusive distribution agreement with China National Medicines Corporation Ltd. for Pralatrexate in China could potentially increase the company's market presence and revenues in the short term.
The exclusive distribution agreement for Pralatrexate in China is likely to be positive for CASI Pharmaceuticals, as it opens up a significant market for the company's product. The one-year duration suggests a trial period that, if successful, could lead to further expansion and partnerships. This deal could lead to increased sales and a stronger foothold in the Chinese market, which is positive for the stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100